New Potential Targeted Strategies in Small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2023 May 17

PMID 37197617

Authors

Maria de Toro

Cristina Pangua

Gloria Serrano-Montero

Miguel Angel Lara

Jacobo Rogado

Affiliations

Soon will be listed here.

References

Chen H, Gesumaria L, Park Y, Oliver T, Singer D, Ge K . BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. Mol Cancer Res. 2022; 21(2):91-101. PMC: 9898120. DOI: 10.1158/1541-7786.MCR-22-0594. View

Majeed S, Aparnathi M, Nixon K, Venkatasubramanian V, Rahman F, Song L . Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer. Clin Cancer Res. 2022; 28(9):1966-1978. PMC: 9365348. DOI: 10.1158/1078-0432.CCR-21-0344. View

Peifer M, Fernandez-Cuesta L, Sos M, George J, Seidel D, Kasper L . Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44(10):1104-10. PMC: 4915822. DOI: 10.1038/ng.2396. View

Gazdar A, Bunn P, Minna J . Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017; 17(12):725-737. DOI: 10.1038/nrc.2017.87. View

Venkatanarayan A, Raulji P, Norton W, Flores E . Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73. Cell Cycle. 2015; 15(2):164-71. PMC: 4825839. DOI: 10.1080/15384101.2015.1121333. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Mani A, Gelmann E . The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005; 23(21):4776-89. DOI: 10.1200/JCO.2005.05.081. View

George J, Lim J, Jang S, Cun Y, Ozretic L, Kong G . Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524(7563):47-53. PMC: 4861069. DOI: 10.1038/nature14664. View

Hyer M, Milhollen M, Ciavarri J, Fleming P, Traore T, Sappal D . A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018; 24(2):186-193. DOI: 10.1038/nm.4474. View

10.

Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed Z . Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022; 18(24):2639-2649. DOI: 10.2217/fon-2022-0196. View

11.

McBride A, Ryan P . Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013; 13(3):339-58. DOI: 10.1586/era.13.9. View

12.

Dingemans A, Fruh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L . Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(7):839-853. PMC: 9464246. DOI: 10.1016/j.annonc.2021.03.207. View

13.

Pangua C, Rogado J, Serrano-Montero G, Belda-Sanchis J, Alvarez Rodriguez B, Torrado L . New perspectives in the management of small cell lung cancer. World J Clin Oncol. 2022; 13(6):429-447. PMC: 9244973. DOI: 10.5306/wjco.v13.i6.429. View

14.

Lochmann T, Floros K, Naseri M, Powell K, Cook W, March R . Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clin Cancer Res. 2017; 24(2):360-369. PMC: 5771805. DOI: 10.1158/1078-0432.CCR-17-1606. View

15.

Jin Y, Chen Y, Tang H, Hu X, Hubert S, Li Q . Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clin Cancer Res. 2021; 28(3):526-539. DOI: 10.1158/1078-0432.CCR-21-1943. View

16.

Wang Y, Suh Y, Fuller M, Jackson J, Xiong S, Terzian T . Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011; 121(3):893-904. PMC: 3049366. DOI: 10.1172/JCI44504. View

17.

Ganti A, Loo B, Bassetti M, Blakely C, Chiang A, DAmico T . Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(12):1441-1464. PMC: 10203822. DOI: 10.6004/jnccn.2021.0058. View

18.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

19.

Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C . Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 2022; 171:26-33. DOI: 10.1016/j.lungcan.2022.07.007. View

20.

Baine M, Hsieh M, Lai W, Egger J, Jungbluth A, Daneshbod Y . SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. J Thorac Oncol. 2020; 15(12):1823-1835. PMC: 8362797. DOI: 10.1016/j.jtho.2020.09.009. View